奥妥珠单抗±苯丁酸氮芥一线治疗CLL的真实世界多中心研究
这项由ERIC和以色列CLL研究组开展的回顾性多国多中心研究,评估了奥妥珠单抗±苯丁酸氮芥一线治疗不适合强化化疗的CLL患者的疗效与安全性。共纳入437例患者(中位年龄75.9岁),总缓解率80.3%,中位无进展生存期27.6个月,2年总生存率88%。高危因素(del(11q22.3)和/或IGHV未突变)、淋巴结>5cm、奥妥珠单抗单药及累积剂量降低与更短PFS独立相关。
要点
- 真实世界中O-Clb一线治疗 unfit CLL 的PFS与临床试验相当,中位PFS 27.6个月。
- del(11q22.3)和/或IGHV未突变、淋巴结>5cm、奥妥珠单抗单药及剂量降低与更短PFS独立相关。
- O-Clb仍可作为低危 unfit CLL 患者的合理一线选择。
核心结论
- 真实世界中O-Clb一线治疗 unfit CLL 的PFS与临床试验报告相当,中位PFS为27.6个月。
- del(11q22.3)和/或IGHV未突变及奥妥珠单抗单药治疗者结局较差。
- O-Clb仍可考虑作为低危 unfit CLL 患者的一线治疗。
研究设计与样本
- 回顾性、多国、多中心协作研究(ERIC与以色列CLL研究组)。
- 纳入437例不适合强化化疗的CLL患者,排除del(17p13.1)/TP53突变者。
- 中位年龄75.9岁,中位CIRS评分8,中位肌酐清除率61.1 mL/min。
主要发现
- 临床总缓解率80.3%,其中完全缓解38.7%,部分缓解41.6%。
- 中位观察时间14.1个月,估计中位PFS为27.6个月(95%CI 24.2-31.0)。
- 中位OS尚未达到,估计2年OS率为88%。
- 多因素分析显示高危疾病[del(11q22.3)和/或IGHV未突变]、淋巴结直径>5cm、奥妥珠单抗单药及累积剂量降低均与更短PFS独立相关。
关键数值与推荐
- O-Clb方案在临床试验中中位PFS为31.5个月。
- 本研究估计中位PFS为27.6个月(95%CI 24.2-31.0)。
- 临床总缓解率80.3%,完全缓解38.7%,部分缓解41.6%。
- 估计2年OS率为88%。
临床怎么用
- O-Clb可作为低危 unfit CLL 患者(无del(11q22.3)和IGHV突变、淋巴结≤5cm)的一线治疗选择。
- 应优先使用奥妥珠单抗联合苯丁酸氮芥而非奥妥珠单抗单药,并保证奥妥珠单抗累积剂量。
- 对存在del(11q22.3)和/或IGHV未突变的高危患者,需考虑替代治疗策略。
局限性
- 回顾性研究设计,可能存在选择偏倚和信息偏倚。
- 中位观察时间仅14.1个月,OS数据尚不成熟。
- 排除del(17p13.1)/TP53突变患者,结论不适用于该高危亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) has been shown to prolong progression free survival (PFS, median PFS-31.5 months) and overall survival (OS) compared to chlorambucil alone. More recently, obinutuzumab given in combination with either ibrutinib or venetoclax improved PFS but not OS when compared to O-Clb. In this retrospective multinational, multicenter co-operative study, we evaluated the efficacy and safety of frontline treatment with O ± Clb in unfit patients with CLL, in a "real-world" setting. Patients with documented del (17p13.1)/TP53 mutation were excluded. A total of 437 patients (median age, 75.9 years; median CIRS score, 8; median creatinine clearance, 61.1 mL/min) were included. The clinical overall response rate was 80.3% (clinical complete and partial responses in 38.7% and 41.6% of patients, respectively). Median observation time was 14.1 months and estimated median PFS was 27.6 months (95% CI, 24.2-31.0). In a multivariate analysis, high-risk disease [del (11q22.3) and/or IGHV-unmutated], lymph nodes of diameter > 5 cm, obinutuzumab monotherapy and reduced cumulative dose of obinutuzumab, were all independently associated with shorter PFS. The median OS has not yet been reached and estimated 2-year OS is 88%. In conclusion, in a "real-world" setting, frontline treatment with O-Clb achieves PFS comparable to that reported in clinical trials. Inferior outcomes were noted in patients with del (11q22.3) and/or unmutated IGHV and those treated with obinutuzumab-monotherapy. Thus, O-Clb can be still considered as legitimate frontline therapy for unfit CLL patients with low-risk disease.
引用
- Herishanu Y, Shaulov A, Fineman R, et al. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group. Am J Hematol. 2020. PMID: 32096887. doi:10.1002/ajh.25766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。